Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Likes Its Critical Mass But Could Amass More; $2 Bil. R&D Will Do

Executive Summary

Roche's restructuring and internal growth obviates the need for a merger, even with the recent loss of several late-phase clinical projects, CEO Franz Humer told the Roche 1999 annual earnings conference March 30 in Basel.

You may also be interested in...



Roche/GSK Boniva Launch Will Await Less Frequent Dose Approval

Roche and GlaxoSmithKline will hold off launching the osteoporosis agent Boniva (ibandronate) until approval of a less frequent dosing regimen

Roche/GSK Boniva Launch Will Await Less Frequent Dose Approval

Roche and GlaxoSmithKline will hold off launching the osteoporosis agent Boniva (ibandronate) until approval of a less frequent dosing regimen

Roche Pares Back To Specialty Care: U.S. Sales Force Will Be Cut By 24%

Roche will concentrate on specialty care products in the U.S. as part of the restructuring of its global pharmaceutical division.

Related Content

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel